DanCann Pharma A/S Reports Fourth Quarter and Full Year 2023 Results
COPENHAGEN, Denmark, 28 February 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has published its report for the fourth quarter of 2023 (“Q4-2023”). The Q4-2023 report is available as an attached document to this press release and at www.dancann.com.
Summary: Group Key Figures Q4-2023
| DKK 1,000 | 01/01/23 –31/12/23 | 01/01/22 –31/12/22 | 01/10/23 – 31/12/23 | 01/10/22 – 31/12/22 | 01/01/22 – 31/12/22 |
| Net sales: | 6,073 | 5,707 | 1,611 | 2,101 | 5,707 |
| Operating profit/loss (EBIT): | -14,124 | -17,586 | -3,219 | -4,343 | -17,586 |
| Result per share (DKK): | -0.09 | -0.58 | -0.02 | -0.20 | -0.52 |
| Equity ratio: | 0.94 | 0.80 | 0.86 | 0.80 | 0.78 |
Number of shares on 31.12.2023 = 141,627,990 (28,468,289)
Result per share = Result for the period / weighted average number of shares
Equity ratio = Equity / Total assets
As part of the Company's revised strategy, it has decided to modify the structure of its quarterly report. Going forward, the Company will continuously report on its financials, down to the product level, as well as on the macroeconomic factors surrounding the market, to ensure the most comprehensive and broad understanding of the case.
About DanCann Pharma A/S
DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.
DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.
For more information, visit: www.dancann.com
For further information, please contact:
Jeppe Krog Rasmussen, CEO
E-mail: [email protected]
Forward-looking-statement:
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.
Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.
Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 28-02-2024.
